# Hangzhou Jianhai Technology Co.

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/hangzhou-jianhai-technology-co

- Industry: Software
- Headquarters: Guangzhou, China
- Website: www.justhealth.cn
- Total disclosed funding: $23M
- Latest round: Series B (Jan 17, 2022)
- Investors on record: 7

## About

Based in China, Hangzhou Jianhai Technology Co., Ltd. focuses on delivering comprehensive digital health services that enhance post-disease management and patient care through advanced online platforms connecting healthcare professionals and patients.Founded in 2015 in Guangzhou, China, Hangzhou Jianhai Technology Co., Ltd. specializes in digital health solutions for post-disease management. The company has successfully secured funding through 2 investment rounds, with the latest being a Series B round of CNY 150.000 mn in January 2022, led by Sequoia Capital and including participation from Sherpa Healthcare Partners and Source Code Capital. The firm operates without any known subsidiaries or parent companies.Hangzhou Jianhai Technology Co., Ltd. specializes in providing comprehensive post-disease management solutions through digital health services. Their core offerings include a robust online platform that connects patients with a network of over 20,000 online doctors and 100,000 online nurses across more than 1,000 hospitals. The company's services leverage a sophisticated disease management knowledge base, developed from collaborations with various healthcare institutions, to facilitate personalized and efficient follow-up care for patients. This technology aims to address the challenges of post-treatment monitoring and ongoing health management, ensuring continuous care that aligns with the evolving needs of patients. Jianhai's solutions are primarily targeted at hospitals and healthcare facilities across various regions, enhancing their operational efficiency and patient care capabilities.Hangzhou Jianhai Technology Co., Ltd. generates revenue through strategic partnerships with hospitals and healthcare systems, focusing on subscription-based models for their digital health services. Clients, including more than 1,000 hospitals, collaborate with Jianhai to integrate their online platforms into existing care workflows, thereby enhancing service delivery and patient engagement. The company’s flagship offering revolves around its digital therapy solutions, which streamline post-disease management processes, contributing to a substantial share of the firm's revenue. Revenue structure is predominantly B2B, with hospitals subscribing to comprehensive service packages that include access to the online doctor network and the disease management knowledge base, ultimately facilitating a seamless integration of digital health solutions into traditional healthcare settings.In January 2022, Hangzhou Jianhai Technology Co., Ltd. raised an undisclosed amount of Series B funding led by Qiming Venture Capital, with participation from Vision Plus Capital, CICC Capital Management, and CD Capital. The company plans to utilize these funds to further expand its R&D pipeline, conduct clinical trials, and supplement its personnel. Future initiatives include the launch of new digital health products aimed at enhancing patient care and the potential expansion into new geographic markets as part of their growth strategy.

## Funding rounds

- Series B, Jan 17, 2022 — Qiming Venture Partners, China International Capital Corporation, Vision Plus Capital, CD Capital
- Series B, Mar 23, 2021, $23M — Hong Shan, Source Code Capital, Sherpa Healthcare Partners

## Investors

- Hong Shan — Series B
- Source Code Capital (https://capitalatlas.ai/funds/source-code-capital) — Series B
- Sherpa Healthcare Partners (https://capitalatlas.ai/funds/sherpa-healthcare-partners) — Series B
- Qiming Venture Partners (https://capitalatlas.ai/funds/qiming-venture-partners) — Series B
- China International Capital Corporation (https://capitalatlas.ai/funds/china-international-capital-corporation) — Series B
- Vision Plus Capital (https://capitalatlas.ai/funds/vision-plus-capital) — Series B
- CD Capital — Series B